Science, Discovery, Tech and Environment · 25 July 2026

ICMR Transfers Indigenous Medical Technologies for Commercialisation

Exam-focused facts from the 25 July 2026 current affairs briefing.

Key facts

  • The Indian Council of Medical Research (ICMR) licensed three indigenous biomedical technologies to pharmaceutical companies for commercialisation.
  • SHetA2, a novel anti-HPV therapeutic candidate for Cervical Intraepithelial Neoplasia (CIN), was licensed to Emcure Pharmaceuticals Ltd.
  • Two next-generation vaccine technologies against enteric bacterial infections, developed at ICMR-National Institute of Research in Bacterial Infections (ICMR-NIRBI), were licensed to Biological E Ltd.
  • The vaccine technologies provide simultaneous protection against Salmonella Typhi and Paratyphi infections and are recombinant protein-based, making them safer and cheaper to produce.

View this story in the full daily briefing

Earlier coverage selected by topic similarity to help connect developments over time.

Draft National Health Research Policy 2026

The draft National Health Research Policy 2026 was released by the Centre and prepared by the Department of Health Research. It proposes a three-tier governance structure comprising a National Health Research Stewardship…